  The natural history of lymphangioleiomyomatosis ( LAM) is mainly derived from retrospective cohort analyses , and it remains incompletely understood. A National Institutes of Health LAM Registry was established to define the natural history and identify prognostic biomarkers that can help guide management and decision-making in patients with LAM. A linear mixed effects model was used to compute the rate of decline of FEV Mean annual decline of FEV The median transplant-free survival in patients with LAM is > 20 years. Menopausal status , as well as structural and physiologic markers of disease severity , significantly affects the rate of decline of FEV